// App-Quantinova.ai

122 : Mutational landscape of highly malignant recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma

Researchers

Presenter

  • R. Cho

Principal Investigators

  • L. Alexandrov

  • M. Jonkman

  • J. McGrath

  • A. Hovnanian

  • J. Bauer

  • L. Bruckner-Tuderman

  • K. Tsai

  • A. South

Medical Centers

  • RDEB SCC Sequencing Consortium, Los Alamos, NM

  • EBHouse Austria, Salzburg, Austria

  • RDEB SCC Sequencing Consortium, London, United Kingdom

  • RDEB SCC Sequencing Consortium, Grognigen, Netherlands

  • University of California, San Francisco, San Francisco, CA

  • TJU, Philadelphia, PA

Locations

  • United States

  • France

  • Austria

  • United Kingdom

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Dermatology

  • Genetic Disorder

Disease

  • Cutaneous squamous cell carcinoma

  • Epidermolysis bullosa

  • Solid malignancies

  • Squamous cell carcinoma of the head and neck

  • Epidermolysis bullosa dystrophica, autosomal recessive

Biomarkers

  • Neurogenic locus notch homolog protein 1

  • AT-rich interactive domain 2

  • Phosphatidylinositol 3-kinase

  • Cyclin Dependent Kinase Inhibitor 2A

  • HRas Proto-Oncogene, GTPase

  • Serpin B3

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved